Compare · ARGX vs NMRA
ARGX vs NMRA
Side-by-side comparison of argenx SE (ARGX) and Neumora Therapeutics Inc. (NMRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and NMRA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $62.50B, about 266.1x NMRA ($234.9M).
- Over the past year, ARGX is up 31.0% and NMRA is down 28.3% - ARGX leads by 59.3 points.
- NMRA has been more active in the news (11 items in the past 4 weeks vs 10 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 23 for NMRA).
- Company
- argenx SE
- Neumora Therapeutics Inc.
- Price
- $1005.45-0.22%
- $1.20-4.00%
- Market cap
- $62.50B
- $234.9M
- 1M return
- +16.07%
- -24.92%
- 1Y return
- +31.05%
- -28.27%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2023
- News (4w)
- 10
- 11
- Recent ratings
- 25
- 23
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Completes Acquisition of Forte Biosciences, Inc.
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Latest NMRA
- Officer Aurora Daljit Singh exercised 176,060 shares at a strike of $0.72 and sold $269,967 worth of shares (176,060 units at $1.53) (SEC Form 4)
- SEC Form 4 filed by Officer Berns Paul L
- SEC Form 4 filed by Officer Duncan Jason
- SEC Form 4 filed by Officer Milligan Michael Lee
- SEC Form 4 filed by President & CEO Pinto Joshua
- SEC Form 144 filed by Neumora Therapeutics Inc.
- SEC Form 144 filed by Neumora Therapeutics Inc.
- Officer Aurora Daljit Singh exercised 243,753 shares at a strike of $0.72 and sold $431,674 worth of shares (277,773 units at $1.55), decreasing direct ownership by 41% to 48,750 units (SEC Form 4)
- SEC Form 144 filed by Neumora Therapeutics Inc.
- SEC Form 144 filed by Neumora Therapeutics Inc.